Sort   by:  
 Page size 
UnknownThe SRSF4-GAS5-Glucocorticoid Receptor Axis Regulates Ventricular Hypertrophy.
Not available
S-EPMC8409900 | biostudies-literature
UnknownGenetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy.
Not available
S-EPMC6613726 | biostudies-literature
UnknownLoss of SRSF3 in Cardiomyocytes Leads to Decapping of Contraction-Related mRNAs and Severe Systolic Dysfunction.
Not available
S-EPMC6615931 | biostudies-literature
UnknownSevere Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3β.
Not available
S-EPMC6784777 | biostudies-literature
UnknownEffect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Not available
S-EPMC10652219 | biostudies-literature
UnknownNuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM.
Not available
S-EPMC12719871 | biostudies-literature
UnknownEfficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
Not available
S-EPMC8048553 | biostudies-literature
UnknownPrevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy.
Not available
S-EPMC11631301 | biostudies-literature
UnknownSeptal thrombus formation after subcutaneous implantable cardioverter shock in a young female with dilated cardiomyopathy.
Not available
S-EPMC9792269 | biostudies-literature
UnknownCoramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.
Not available
S-EPMC12851541 | biostudies-literature
Sort   by:  
 Page size